Thank you for joining the weekly webinar!
We are admitting audience members from the waiting room.
Please allow a few moments for the webinar to begin.
HEALEY ALS Platform Trial

Weekly Q&A – March 7, 2024

Massachusetts General Hospital
Founding Member, Mass General Brigham

Healey & AMG Center
Sean M. Healey & AMG Center for ALS
at Massachusetts General Hospital

NEALS
Northeast Amyotrophic Lateral Sclerotic Consortium

NEUROLOGICAL CLINICAL RESEARCH INSTITUTE

The Arthur M. Blank Family Foundation
This trial is dedicated to all people living with ALS, their families, and friends. Your partnership in research is what keeps us filled with passion, dedication, and the commitment to develop new treatments for ALS.

This breakthrough trial would not be possible without your participation.

Every research participant, whether on the active drug or placebo, plays a critical role in making the hope of finding a cure for ALS a reality.

Thank You
Common protocol and shared infrastructure allow for operational and scientific efficiencies

1 Protocol (Phase 2/3)
1 single IRB
Central Governance

7 Regimens
70+ Enrolling Sites
~1300 Participants

Regimen: Active Study Drug + Matching Placebo
The objective of each regimen is to provide a go / no go decision to inform the clinical development program of the regimen study drug.

**Primary Endpoint (Placebo-Controlled Period)**
Change from baseline through week 24 in disease severity as measured by the ALSFRS-R total score and survival.

**Safety, Secondary, and Exploratory Endpoints**
(respiratory function, muscle strength, survival, biomarkers + regimen-specific endpoints)
Enrollment Update: Regimen F and Regimen G

- 654 participants consented to Master Protocol since RGF and RGG initiated.
- 549 participants assigned to RGF or RGG.
- 483 participants randomized within RGF or RGG.

Thank You for your partnership in ALS research.

(as of 3/7/24)
Providing research access across a diverse network of 70+ NEALS sites

Contact a study team near you to discuss enrollment opportunities

https://bit.ly/3g2NZr5
Monthly Expanded Access Q&A Webinars

February 8, 2024 –
EAP Talk with Dr. Rick Bedlack and Gwen Petersen

January 11, 2024 –
EAP Discussion with the NIH

December 14, 2023 –
EAP Update with Dr. James Berry (MGH)
Recording: https://bit.ly/3UfCAJU

March 14, 2024 – Thurs 5:00-5:30 EST
EAP Update with Dr. Jinsy Andrews (Columbia)
Expanded Access Resources and Webinar Opportunities

Join us for updates about Expanded Access and EAPs on the second Thursday of each month!
(or view recordings online)

Visit the NEALS website to explore upcoming educational webinar opportunities or view previous recordings

Find more webinar opportunities and recordings through the International Alliance of ALS/MND Associations

https://bit.ly/3r6Nd2L
https://bit.ly/3S4P0Sb
https://bit.ly/3Obj2m6
March 18, 2024

**The Science Behind ALS Treatments: Riluzole, Radicava, and Relyvrio Description**

Moderated by Dr. Senda Ajroud-Driss, this webinar for both clinicians and people living with ALS will review the 3 drugs that are currently FDA-approved in the United States for the general ALS population. Panelists, Dr. Lauren Elman, ...

**Register Here:**

https://bit.ly/3S4P0Sb

*Recording will later be available under “educational webinars” on neals.org*
Patient Navigation
Central resource for people living with ALS

Phone: 833-425-8257 (HALT ALS)
E-mail: healeyalsplatform@mgh.harvard.edu

Weekly webinar registration: [QR Code]

ALS Link sign-up: [QR Code]

Upcoming Webinars:
March 14th- EAP Discussion with Dr. Jinsy Andrews (Columbia University)
March 21st- Weekly Q&A Featuring Karen Parada (University of Chicago)
March 28th- Weekly Q&A